{"id":"https://genegraph.clinicalgenome.org/r/4bbce51d-275a-4522-92fd-5cbfb229ba7fv1.1","type":"EvidenceStrengthAssertion","dc:description":"CFH was first reported in relation to semidominant atypical hemolytic uremic syndrome (aHUS) in 1998 (Warwicker et al., PMID: 9551389). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found differences in phenotypic variability. Therefore, the following diseases have been split into separate entities, aHUS (OMIM: 235400) and C3 glomerulopathy (C3G) (OMIM: 609814). The split curation for semidominant C3G will be conducted separately. Fourteen variants (missense, nonsense, frameshift) that have been reported in eleven probands in three publications (PMIDs: 12424708, 14978182, 28941939) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is known to be loss of function. This gene-disease relationship is also supported by experimental evidence (animal models, in vitro functional assays, and biochemical function) (PMIDs: 83964, 16338962, 17517971, 28057640).\n\nOne mouse model (PMID 17517971 lacking the terminal five SCR cell surface recognition domains of factor H (FHΔ16-20) controlled C3 turnover in plasma but defective control of complement activation on renal endothelium resulted in aHUS. A subsequent mouse (PMID: 28057640) carried a homozygous W1206R missense change in mouse FH that corresponded to the W1183R missense variant in human FH found in multiple aHUS families. This again led to impaired FH activity on cell surface and an aHUS phenotype in the mouse model.\n\nGenerally, CFH is known to inhibit C3 function (PMID: 83964) and the C-terminal region of CFH is known to be responsible for cell surface binding and complement regulation via glycosaminoglycan and C3b/C3d (PMID: 18684951). Multiple variants in this region of CFH were shown to reduce heparin affinity as well as binding with C3b/C3d (PMID: 16338962) resulting in aHUS.\n\nOf note, some variants in CFH can cause aHUS and/or C3G in separate patients, although the mechanism of disease leading to different clinical presentations is not fully understood. In summary, there is definitive evidence supporting the relationship between CFH and semidominant aHUS. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over. This classification was approved by the ClinGen Complement Mediated Kidney Diseases GCEP on the meeting date April 19, 2023 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/4bbce51d-275a-4522-92fd-5cbfb229ba7f","GCISnapshot":"https://genegraph.clinicalgenome.org/r/b0a234f8-1d8e-4a26-a76f-40219591c75c","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/b0a234f8-1d8e-4a26-a76f-40219591c75c_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10069","date":"2023-07-02T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/b0a234f8-1d8e-4a26-a76f-40219591c75c_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10069","date":"2023-09-29T15:51:22.914Z","role":"Publisher"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b0a234f8-1d8e-4a26-a76f-40219591c75c_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b0a234f8-1d8e-4a26-a76f-40219591c75c_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1f5dab38-d4a0-42da-89fb-632185e04863","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/300f29fe-c60b-43ee-b57a-ba5a1f453bac","type":"Finding","dc:description":"CFH deficiency leads to C3 consumption in patients, driving the occurrence of aHUS.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/83964","rdfs:label":"CFH Functional Characterization","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b0a234f8-1d8e-4a26-a76f-40219591c75c_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91b8f024-7055-424a-83b4-d379cedc50b2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3743617-8224-4720-bb4c-b8a197c3c5bb","type":"FunctionalAlteration","dc:description":"All variants showed a reduction in heparin affinity as well as C3b/C3d binding.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16338962","rdfs:label":"Heparin and C3b/C3d binding affinity"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b0a234f8-1d8e-4a26-a76f-40219591c75c_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d28f7e3-d68f-48b6-a1af-bf8fa7aefd14","type":"EvidenceLine","dc:description":"This mouse model was upgraded by the Complement Mediated Kidney Diseases GCEP due to it replicating the disease with a variant analogous to one that's been reported in heterozygote patients with aHUS carrying this variant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4784d8f5-4094-488f-95a0-b02f0b78e18b","type":"Finding","dc:description":"The mouse model harboring a homozygous variant homologous to one seen in multiple families with aHUS presented with a phenotype replicating TMA. While W1206R mutation in murine FH caused a reduction in plasma complement levels, it led to increased complement activity on the cell surface due to impaired interaction of FH with host cells. Of 147 R/R mice, 48% died by 30 weeks.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28057640","rdfs:label":"Mouse with variant analogous to W1183R","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/eb603b0f-0fb8-4e91-aecf-7e7e788166e7","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d6085c8-50ad-429a-82f7-4addf2e08346","type":"Finding","dc:description":"Cfh -/- mice regulate C3 activation in plasma and spontaneously develop aHUS. The model functionally mimicked aHUS-associated human FH mutations. Cfh −/− mice expressing this mutant FH protein spontaneously developed aHUS, not MPGN. It was demonstrated that specifically impairing surface recognition can result in spontaneous aHUS and define the molecular pathogenesis of aHUS-associated FH mutations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17517971","rdfs:label":"FH-deficient mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5},{"id":"https://genegraph.clinicalgenome.org/r/b0a234f8-1d8e-4a26-a76f-40219591c75c_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42529178-a67b-41e3-9a77-ebe4285289a5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42529178-a67b-41e3-9a77-ebe4285289a5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14978182","rdfs:label":"Dragon-Durey Patient 8","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":16,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e01bf3f0-18f3-4362-96ce-120295baf59c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.2300dup (p.Asn767LysfsTer8)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2579983775"}},"firstTestingMethod":"PCR","phenotypeFreeText":"HUS at 16 months","phenotypes":"obo:HP_0012622","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e728c054-21a8-4f5f-9d86-49ebf05c9966_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14978182","allele":{"id":"https://genegraph.clinicalgenome.org/r/e01bf3f0-18f3-4362-96ce-120295baf59c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e728c054-21a8-4f5f-9d86-49ebf05c9966","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e728c054-21a8-4f5f-9d86-49ebf05c9966_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/11756b60-32ea-4fe8-9fc8-1fc5c919c8b6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11756b60-32ea-4fe8-9fc8-1fc5c919c8b6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","rdfs:label":"Merinero Proband 1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":24,"allele":{"id":"https://genegraph.clinicalgenome.org/r/fc1ba596-37bc-44e4-a279-0c3cd3a61ca7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.157C>T (p.Arg53Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1304957"}},"firstTestingMethod":"Exome sequencing","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3ac837eb-938e-4e93-9843-e2d63fedb511_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","allele":{"id":"https://genegraph.clinicalgenome.org/r/fc1ba596-37bc-44e4-a279-0c3cd3a61ca7"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3ac837eb-938e-4e93-9843-e2d63fedb511","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ac837eb-938e-4e93-9843-e2d63fedb511_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/3ac837eb-938e-4e93-9843-e2d63fedb511_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Completely lacks decay-accelerating activity. Significantly reduced fluid-phase FI cofactor activities compared with WT FH protein.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/742dafd9-7184-4bf7-bb4b-bfb8c7908e20_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/742dafd9-7184-4bf7-bb4b-bfb8c7908e20","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12424708","rdfs:label":"HUS3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":55,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f3711d5f-906e-4d8f-8c9c-864b71ac8467","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.3590T>C (p.Val1197Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341616"}},"phenotypeFreeText":"Hemodialysis","phenotypes":"obo:HP_0003774","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/fb1a36b8-734f-4917-ad4a-9aa34d736251_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12424708","allele":{"id":"https://genegraph.clinicalgenome.org/r/f3711d5f-906e-4d8f-8c9c-864b71ac8467"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}},"zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/fb1a36b8-734f-4917-ad4a-9aa34d736251","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb1a36b8-734f-4917-ad4a-9aa34d736251_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/fb1a36b8-734f-4917-ad4a-9aa34d736251_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Decreased binding of FH to surface-bound C3b. Decreases affinity to heparin (Józsi et al. 2006, PMID:16338962).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/606d3753-82de-46b2-a4ab-54e44fd105f5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/606d3753-82de-46b2-a4ab-54e44fd105f5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","rdfs:label":"Merinero Proband 10","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":42,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4d24494f-3724-4349-a116-f141e9bceff0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000001.11:g.196673963del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573106150"}},"firstTestingMethod":"Exome sequencing","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/837536c6-d066-45e1-9eae-65fd8aaae3f2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","allele":{"id":"https://genegraph.clinicalgenome.org/r/4d24494f-3724-4349-a116-f141e9bceff0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/837536c6-d066-45e1-9eae-65fd8aaae3f2","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/837536c6-d066-45e1-9eae-65fd8aaae3f2_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/837536c6-d066-45e1-9eae-65fd8aaae3f2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This variant results in very low, almost absent, levels of FH in plasma.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/615c1233-34df-489a-8ec5-ab1753c783d2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/615c1233-34df-489a-8ec5-ab1753c783d2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14978182","rdfs:label":"Dragon-Durey Patient 7","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"allele":{"id":"https://genegraph.clinicalgenome.org/r/853608bd-3855-4828-8421-3087360f2b8d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.2773C>T (p.Gln925Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343994631"}},"firstTestingMethod":"PCR","phenotypeFreeText":"HUS at 6 months","phenotypes":"obo:HP_0012622","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/04d81b60-251e-475e-9e77-4763c32c0ce3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14978182","allele":{"id":"https://genegraph.clinicalgenome.org/r/853608bd-3855-4828-8421-3087360f2b8d"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/04d81b60-251e-475e-9e77-4763c32c0ce3","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/04d81b60-251e-475e-9e77-4763c32c0ce3_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/41fdc309-9c49-4192-8e97-9ea6a8a10cee_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/41fdc309-9c49-4192-8e97-9ea6a8a10cee","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14978182","rdfs:label":"Dragon-Durey Patient 9","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":18,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4c55ec76-30e6-4c2a-a785-2fd144f50987","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.372_396del (p.Ile124MetfsTer13)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2579983776"}},"firstTestingMethod":"PCR","phenotypeFreeText":"HUS at 18 months and death 6 months after.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/8e3e6350-159a-49a0-8478-b09a123138c5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14978182","allele":{"id":"https://genegraph.clinicalgenome.org/r/4c55ec76-30e6-4c2a-a785-2fd144f50987"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/8e3e6350-159a-49a0-8478-b09a123138c5","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8e3e6350-159a-49a0-8478-b09a123138c5_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/28de446a-309a-4661-831b-f8e52fe7639e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/28de446a-309a-4661-831b-f8e52fe7639e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","rdfs:label":"Merinero Proband 28","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":30,"allele":{"id":"https://genegraph.clinicalgenome.org/r/9b6f9f41-0601-41ae-88d7-de6cee1077a1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.3493+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343986440"}},"firstTestingMethod":"Exome sequencing","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3c52fa44-86a6-42a3-9270-776feb81219c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","allele":{"id":"https://genegraph.clinicalgenome.org/r/9b6f9f41-0601-41ae-88d7-de6cee1077a1"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3c52fa44-86a6-42a3-9270-776feb81219c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3c52fa44-86a6-42a3-9270-776feb81219c_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/3c52fa44-86a6-42a3-9270-776feb81219c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This variant results in a serum FH reduction of >50%.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7e761001-b934-4e04-8316-406d0c03c29c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e761001-b934-4e04-8316-406d0c03c29c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","rdfs:label":"Merinero Proband 2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":36,"allele":{"id":"https://genegraph.clinicalgenome.org/r/0009c4db-4a64-45cc-b069-e438235e0477","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.157C>A (p.Arg53Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343995947"}},"firstTestingMethod":"Exome sequencing","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/88103c01-412e-4269-8f09-f1e175752eb7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","allele":{"id":"https://genegraph.clinicalgenome.org/r/0009c4db-4a64-45cc-b069-e438235e0477"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/88103c01-412e-4269-8f09-f1e175752eb7","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88103c01-412e-4269-8f09-f1e175752eb7_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/88103c01-412e-4269-8f09-f1e175752eb7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Significantly reduced capacity to regulate alternative pathway in modified sheep red blood cell hemolytic assay. Surface plasmon resonance demonstrated complete lack of decay-accelerating activity. Significantly reduced fluid-phase FI cofactor activity","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/2f2f917f-202a-42c1-925b-d37fa9fed407_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f2f917f-202a-42c1-925b-d37fa9fed407","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12424708","rdfs:label":"HUS2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":25,"allele":{"id":"https://genegraph.clinicalgenome.org/r/43c3f6cc-5500-463e-b7f9-f4a8d70d9c46","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.3548G>T (p.Trp1183Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343987433"}},"phenotypeFreeText":"Kidney transplanted twice, hemodialysis","phenotypes":"obo:HP_0003774","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/1f0a45fe-3066-4615-93b7-b2e7b5899e7e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12424708","allele":{"id":"https://genegraph.clinicalgenome.org/r/43c3f6cc-5500-463e-b7f9-f4a8d70d9c46"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/1f0a45fe-3066-4615-93b7-b2e7b5899e7e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1f0a45fe-3066-4615-93b7-b2e7b5899e7e_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/1f0a45fe-3066-4615-93b7-b2e7b5899e7e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Significantly lower capacity to bind to surface-bound C3b than WT FH.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1e9bc8bd-e309-4f30-97bd-e29139fa403c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e9bc8bd-e309-4f30-97bd-e29139fa403c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","rdfs:label":"Merinero Proband 27","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"allele":{"id":"https://genegraph.clinicalgenome.org/r/aac23c2f-659b-4a6a-9d2f-b8511a582284","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.3355G>A (p.Asp1119Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343985155"}},"firstTestingMethod":"Exome sequencing","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/f9921e82-6390-4fe2-893e-1e5fea2715a3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28941939","allele":{"id":"https://genegraph.clinicalgenome.org/r/aac23c2f-659b-4a6a-9d2f-b8511a582284"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f9921e82-6390-4fe2-893e-1e5fea2715a3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f9921e82-6390-4fe2-893e-1e5fea2715a3_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f9921e82-6390-4fe2-893e-1e5fea2715a3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Significantly reduced capacity to regulate alternative pathway in modified sheep red blood cell hemolytic assay. Surface plasmon resonance demonstrated complete lack of decay-accelerating activity. Impaired C-terminal C3b binding. From Merinero et al., 2021 (PMID: 34189567) abnormal GP hemolysis HR50, DAA, FI cofactor activity.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1bb510ba-6c92-44ec-9cb2-949d65bdfa87_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1bb510ba-6c92-44ec-9cb2-949d65bdfa87","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14978182","rdfs:label":"Dragon-Durey Patient 1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":7,"allele":{"id":"https://genegraph.clinicalgenome.org/r/412fdbde-3023-4c05-a799-b5f3a886d778","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000186.4(CFH):c.2697T>A (p.Tyr899Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA257510"}},"firstTestingMethod":"PCR","phenotypeFreeText":"Relapsing HUS since 7 months","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/15d0d127-c35d-4c4e-be1c-3905dc572b22_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14978182","allele":{"id":"https://genegraph.clinicalgenome.org/r/412fdbde-3023-4c05-a799-b5f3a886d778"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:BiallelicHomozygous"}},"zygosity":{"id":"cg:BiallelicHomozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/15d0d127-c35d-4c4e-be1c-3905dc572b22","type":"EvidenceLine","dc:description":"This variant was downgraded by 0.5 points for both consanguinity and homozygosity.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15d0d127-c35d-4c4e-be1c-3905dc572b22_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":7009,"specifiedBy":"GeneValidityCriteria9","strengthScore":17,"subject":{"id":"https://genegraph.clinicalgenome.org/r/KDOnMVC_8xw","type":"GeneValidityProposition","disease":"obo:MONDO_0016244","gene":"hgnc:4883","modeOfInheritance":"obo:HP_0032113"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_b0a234f8-1d8e-4a26-a76f-40219591c75c-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}